|
시장보고서
상품코드
2159823
비오티니다아제 결핍증 시장 규모, 점유율, 성장 분석 : 진단별, 치료별, 환자층별, 최종사용자별, 지역별 - 산업 예측(2026-2033년)Biotinidase Deficiency Market Size, Share, and Growth Analysis, By Diagnosis (Newborn Screening, Enzyme Activity Testing), By Treatment (Biotin Supplementation, Dietary Management), By Patient Group, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 비오티니다아제 결핍증 시장 규모는 2024년에 5억 50만 달러로 평가되며, 2025년 5억 1,952만 달러에서 2033년까지 7억 14만 달러로 확대되어, 예측 기간(2026-2033년) 동안 CAGR 3.8%로 성장할 것으로 전망됩니다.
세계 비오티니다아제 결핍증 시장은 비타민 B7의 재순환에 영향을 미치는 희귀 유전 질환에 대한 진단, 치료 및 모니터링 솔루션을 중심으로 구성되어 있습니다. 이 질환은 치료를 받지 않을 경우 심각한 신경학적 장애나 발달 지연을 유발할 수 있으므로, 효과적인 관리가 매우 중요합니다. 시장 성장은 주로 신생아 선별 검사 프로그램의 확대에 의해 주도되고 있으며, 이로 인해 검출률이 크게 향상되어 확진 검사 및 치료에 대한 수요가 증가하고 있습니다. 재조합 효소 대체 요법(ERT)의 개발과 도입도 시장 성장을 더욱 뒷받침하고 있으며, ERT를 도입한 병원에서는 환자 예후 개선 및 의료비 절감 효과가 보고되고 있습니다. 또한, AI의 발전으로 진단이 신속해지고 맞춤형 치료 경로가 가능해졌으며, 의료 제공자 간의 협력이 강화되어 궁극적으로 정밀 의학의 추진으로 이어지고 있습니다. 아울러 신흥 경제국들도 새로운 시장 기회를 제공하고 있습니다.
세계 비오티니다아제 결핍증 시장의 성장요인
일반 대중과 의료 종사자 모두에게서 비오티니다아제 결핍증에 대한 인식이 높아지고 있는 것은 시장을 견인하는 중요한 요인입니다. 이 질환에 대한 지식이 깊어짐에 따라 조기 진단과 조기 개입이 더욱 중요시되고 있으며, 이는 진단 도구 및 치료 솔루션에 대한 수요 증가로 이어지고 있습니다. 인식 제고 캠페인과 환자 지원 단체는 이 질환의 관리에 관한 정보를 확산하는 데 있어 매우 중요한 역할을 수행하고 있으며, 의료 종사자에 의한 선별 검사 실시와 의사에 의한 적절한 효소 보충 요법 처방을 촉진하고 있습니다. 이러한 관심 증대는 환자층을 확대할 뿐만 아니라, 보험사 및 제약사의 신뢰도도 조성하고 있습니다. 또한, 공동 연구 활동은 혁신적인 치료법 개발을 더욱 촉진하여 시장의 성장을 지속시키고 있습니다.
세계 비오티니다아제 결핍증 시장의 제약요인
세계 비오티니다아제 결핍증 시장은 효소 보충 요법 및 전문 진단 도구와 관련된 고비용으로 인해 큰 과제에 직면해 있습니다. 이러한 경제적 장벽은 특히 보상 수단이 부족한 저소득 지역의 환자와 의료 시스템에 심각한 영향을 미치고 있습니다. 보험사는 보험 적용을 승인하기 전에 임상적 유효성에 대한 종합적인 증거를 요구하는 경우가 많으며, 그 결과 치료가 필요한 많은 사람들에게 승인 지연이나 거부가 발생하고 있습니다. 이러한 경제적 제약은 시장 성장을 저해하며, 임상적 필요성이 있음에도 불구하고 제약사가 가격에 민감한 지역에 집중하는 것을 방해하고 있습니다. 그 결과, 의료 서비스 제공자는 대체적이고 효능이 낮은 치료법에 의존할 수밖에 없게 되어, 승인된 치료법의 보급을 더욱 저해할 가능성이 있습니다.
세계 비오티니다아제 결핍증 시장의 동향
세계 비오티니다아제 결핍증 시장에서는 유전체 스크리닝 활동의 확대에 힘입어 뚜렷한 동향이 나타나고 있습니다. 신생아용 유전체 패널 및 보인자 검사 프로그램의 도입이 확대됨에 따라, 폭넓은 계층에서 비오티니다아제 결핍증의 조기 발견이 촉진되고 있습니다. 임상의들은 효소 결핍증 및 관련 대사 질환을 확인하기 위해 첨단 멀티플렉스 차세대 염기서열 분석 기술을 점점 더 많이 활용하고 있으며, 이를 통해 적시 개입이 가능해졌습니다. 이러한 예방적 진단으로의 전환은 질환의 잠복기를 최소화하고 환자의 예후를 개선할 뿐만 아니라, 맞춤형 치료 전략의 추진으로도 이어지고 있습니다. 의료 시스템이 예방 조치로서의 종합적인 유전자 선별 검사의 가치를 인식함에 따라, 보험사들도 검사 비용의 환급을 지원하기 시작했으며, 전 세계적으로 검사 기관, 소아 의료 네트워크, 전문 클리닉 간의 협력이 촉진되고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 비오티니다아제 결핍증 시장 규모 : 진단별
세계의 비오티니다아제 결핍증 시장 규모 : 치료별
세계의 비오티니다아제 결핍증 시장 규모 : 환자 그룹별
세계의 비오티니다아제 결핍증 시장 규모 : 최종사용자별
세계의 비오티니다아제 결핍증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSMGlobal Biotinidase Deficiency Market size was valued at USD 500.5 Million in 2024 and is poised to grow from USD 519.52 Million in 2025 to USD 700.14 Million by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).
The global biotinidase deficiency market is centered around diagnostic, therapeutic, and monitoring solutions for a rare genetic disorder affecting vitamin B7 recycling. This condition can lead to severe neurological issues and developmental delays if untreated, making effective management crucial. Growth in the market is primarily driven by the expansion of newborn screening programs, significantly increasing detection rates and demand for confirmatory tests and treatments. The development and integration of recombinant enzyme replacement therapy (ERT) further bolster market growth, as hospitals adopting ERT report improved patient outcomes and reduced healthcare costs. Additionally, advancements in AI facilitate faster diagnosis and personalized treatment pathways, enhancing collaboration among healthcare providers and ultimately promoting precision medicine, while emerging economies present new market opportunities.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biotinidase Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biotinidase Deficiency Market Segments Analysis
Global biotinidase deficiency market is segmented by diagnosis, treatment, patient group, end user and region. Based on diagnosis, the market is segmented into Newborn Screening, Enzyme Activity Testing, Genetic Testing, Molecular Testing and Others. Based on treatment, the market is segmented into Biotin Supplementation, Dietary Management and Supportive Therapy. Based on patient group, the market is segmented into Infants, Children, Adolescents and Adults. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Specialty Clinics, Research Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Biotinidase Deficiency Market
The rising awareness among both the public and healthcare professionals regarding biotinidase deficiency is a significant factor propelling the market. As knowledge about the condition grows, early diagnosis and intervention are becoming more prioritized, driving an increased demand for diagnostic tools and therapeutic solutions. Educational campaigns and patient advocacy organizations play a crucial role in spreading information related to the management of the condition, encouraging healthcare providers to implement screening procedures and practitioners to prescribe suitable enzyme replacement therapies. This elevated interest not only expands the patient base but also instills confidence among payers and manufacturers, while collaborative research efforts further enhance the development of innovative treatments, sustaining market growth.
Restraints in the Global Biotinidase Deficiency Market
The Global Biotinidase Deficiency market faces substantial challenges due to the high expenses linked with enzyme replacement therapy and specialized diagnostic tools. These financial barriers particularly affect patients and healthcare systems in low-income areas, where reimbursement avenues are scarce. Insurers often demand comprehensive evidence of clinical effectiveness prior to granting coverage, resulting in delays or denials for many individuals in need. Such economic limitations hinder market growth and deter manufacturers from focusing on price-sensitive regions, despite the clinical necessity. As a result, healthcare providers may resort to alternative and less effective treatment approaches, further impeding the acceptance of approved therapies.
Market Trends of the Global Biotinidase Deficiency Market
The Global Biotinidase Deficiency market is witnessing a significant trend driven by the expansion of genomic screening initiatives. The growing integration of newborn genomic panels and carrier-testing programs is enhancing the early detection of biotinidase deficiency among a wide range of populations. Clinicians are increasingly utilizing advanced multiplex next-generation sequencing techniques to identify enzyme deficiencies and associated metabolic disorders, leading to timely interventions. This shift towards proactive diagnostics not only minimizes disease latency and enhances patient outcomes but also promotes personalized care strategies. As health systems recognize the value of comprehensive genetic screening as a preventive measure, insurers are beginning to support testing reimbursement, fostering collaboration among laboratories, pediatric networks, and specialty clinics on a global scale.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porter's Analysis & Impact
- Competitive Rivalry
- Threat of Substitutes
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Biotinidase Deficiency Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Newborn Screening
- Enzyme Activity Testing
- Genetic Testing
- Molecular Testing
- Others
Global Biotinidase Deficiency Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Biotin Supplementation
- Dietary Management
- Supportive Therapy
Global Biotinidase Deficiency Market Size by Patient Group & CAGR (2026-2033)
- Market Overview
- Infants
- Children
- Adolescents
- Adults
Global Biotinidase Deficiency Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Diagnostic Laboratories
- Specialty Clinics
- Research Institutions
- Others
Global Biotinidase Deficiency Market Size & CAGR (2026-2033)
- North America (Diagnosis, Treatment, Patient Group, End User)
- US
- Canada
- Europe (Diagnosis, Treatment, Patient Group, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Diagnosis, Treatment, Patient Group, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Diagnosis, Treatment, Patient Group, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Diagnosis, Treatment, Patient Group, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- BioMarin Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ultragenyx Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alexion Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Orpharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Recordati Rare Diseases
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chiesi Global Rare Diseases
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Horizon Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rare Disease Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Centogene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Invitae
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GeneDx
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Labcorp
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quest Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ARUP Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mayo Clinic Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fulgent Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
